Meeting report : first meeting of the task force cytokines of the EORTC research branchZWIERZINA, H.European journal of cancer : (1990). 1991, Vol 27, Num 6, pp 789-795Article

Practical aspects of cytokine therapyZWIERZINA, H.Stem cells (Dayton, OH). 1993, Vol 11, Num 3, pp 144-153, issn 1066-5099Article

Biomarkers in drug developmentZWIERZINA, H.Annals of oncology. 2008, Vol 19, issn 0923-7534, v33-v37, SUP5Conference Paper

Increased serum interleukin 6 levels in patients with myelodysplastic syndromesHEROLD, M; SCHMALZL, F; ZWIERZINA, H et al.Leukemia research. 1992, Vol 16, Num 6/7, pp 585-588, issn 0145-2126Article

GM-CSF state of the art and future perspectivesZWIERZINA, H; NüSSLER, V.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, issn 1359-6349, 43 p.Serial Issue

Delayed maturation of skin window macrophages in myelodysplastic syndromesZWIERZINA, H; SEPP, N; RINGLER, E et al.Leukemia research. 1989, Vol 13, Num 7, pp 433-435, issn 0145-2126Article

Phase i trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development GroupSCHÖFFSKI, P; RIGGERT, S; WILHELM-OGUNBIYI, K et al.Annals of oncology. 2004, Vol 15, Num 12, pp 1816-1824, issn 0923-7534, 9 p.Article

GM-CSF can cause T cell activation; Results of sequential chemo-immunotherapyGROENEWEGEN, G; DE GAST, G. C.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S23-S24, issn 1359-6349Article

Two distinct cell populations are obtained from human blood monocytes cultured with M-CSF, GM-CSF and IL-4BARON, C. L; SCHOLL, S. M; BAUSINGER, H et al.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S39-S40, issn 1359-6349Article

Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failureJAKOB, G; MAIR, J; VORDERWINKLER, K.-P et al.Clinical chemistry (Baltimore, Md.). 1994, Vol 40, Num 1, pp 96-100, issn 0009-9147Article

Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF)GERHARTZ, H. H; MARCUS, R; HOFFBRAND, A. V et al.Infection. Supplement. 1992, Vol 20, Num 2, pp S116-S123, issn 0173-2129Article

Market and patient access to new oncology products in Europe : a current, multidisciplinary perspectiveMCCABE, C; BERGMANN, L; PASCHEN, B et al.Annals of oncology. 2009, Vol 20, Num 3, pp 403-412, issn 0923-7534, 10 p.Article

Combination of GM-CSF with antitumour vaccine strategiesGAUDERNACK, G; GJERTSEN, M. K.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S33-S35, issn 1359-6349Article

Use of granulocyte-macrophage colony stimulating factor (GM-CSF) in prevention and treatment of fungal infectionsJONES, T. C.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S8-S10, issn 1359-6349Article

Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cellsMARTH, C; ZEIMET, A. G; HEROLD, M et al.International journal of cancer. 1996, Vol 67, Num 6, pp 826-830, issn 0020-7136Article

A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemiaGERHARTZ, H. H; MARCUS, R; FIERE, D et al.Leukemia. 1994, Vol 8, Num 1, pp 16-23, issn 0887-6924Article

Depression of histone acetylation by alkylating antitumor agents in murine cells = Diminution de l'acétylation des histones par les agents antitumoraux alkylants dans les cellules murinesZWIERZINA, H; LOIDL, A; FUITH, L. C et al.Cancer research (Baltimore). 1984, Vol 44, Num 8, pp 3336-3339, issn 0008-5472Article

Present and future breast cancer management-bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryBARTSCH, R; FRINGS, S; HENDRIKS, H. R et al.Annals of oncology. 2014, Vol 25, Num 4, pp 773-780, issn 0923-7534, 8 p.Article

Second consensus on medical treatment of metastatic breast cancerBESLIJA, S; BONNETERRE, J; MENARD, S et al.Annals of oncology. 2007, Vol 18, Num 2, pp 215-225, issn 0923-7534, 11 p.Article

GM-CSF as adjuvant for immunotherapy with bispecific antibodiesELSÄSSER, D; STADICK, H; VAN DE WINKEL, J. G. J et al.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S25-S28, issn 1359-6349Article

Molecular aspects of the GM-CSF receptor: An example of the cell signalling mechanisms used by type 1 cytokine receptorsLEAKE, R.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S2-S3, issn 1359-6349Article

Local use of GM-CSF for severe mucositisHEJNA, M; BRODOWICZ, T; ZIELINSKI, C. C et al.European journal of cancer. Supplement (1990). 1999, Vol 35, Num 3, pp S14-S17, issn 1359-6349Article

Image analysis detects lineage-specific morphologic markers in leukemic blast cellsBAUMANN, I; NENNINGER, R; HARMS, H et al.American journal of clinical pathology. 1996, Vol 105, Num 1, pp 23-30, issn 0002-9173Article

Stimulation of colony formation of various human carcinoma cell lines by rhGM-CSF and rhIL-3NACHBAUR, D; DENZ, H; ZWIERZINA, H et al.Cancer letters. 1990, Vol 50, Num 3, pp 197-201, issn 0304-3835, 5 p.Article

Page / 3